ArticleThe Journal of clinical investigation2018

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.

Yared Hailemichael et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.